Clearmind completes Part A dosing in Phase I/II CMND-100 trial for alcohol use disorder

• Clearmind Medicine completed treatment for all 24 participants in Part A of its FDA-regulated Phase I/II trial of CMND-100 in Alcohol Use Disorder.
• Results have not been presented yet; the dataset is under review.
• The company plans to move to the next stage in AUD patients if the data review remains favorable.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607280747PRIMZONEFULLFEED9799215) on July 28, 2026, and is solely responsible for the information contained therein.